Sensorion Aktie [WKN DE: A14SVV / ISIN: FR0012596468]

Kurse + Charts + Realtime		News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (groß)	News + Adhoc	Bilanz/GuV	Termine	Zertifikate	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil	Optionsscheine	Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV	Knock-Outs
Historisch	Analysen

Kurse + Charts + Realtime
Kurs + Chart
Times + Sales
Börsenplätze
Historisch

News + Analysen
News + Adhoc
Analysen
Kursziele

Fundamental
Bilanz/GuV
Schätzungen
Dividende/GV
Analysen

Unternehmen
Termine
Profil

zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs

Nachrichten zu Sensorion SA

06.11.24		Sensorion Announces Its Participation in Upcoming Investor Conferences to be Held in November 2024 (Businesswire)
17.10.24		Sensorion Announces its Participation in the 31st Annual Congress of the European Society of Gene and Cell Therapy and the Presentation of Several Posters on GJB2-GT (Businesswire)
26.09.24		Sensorion Announces Webconference for Retail Shareholders on October 10, 2024 (Businesswire)
23.09.24		Sensorion Announces the Availability of its Half Year 2024 Report (Businesswire)
23.09.24		Sensorion Reports New Positive Clinical Results Presented at the World Congress of Audiology (Businesswire)
20.09.24		Sensorion Announces New Positive Clinical Data Across its Gene Therapy and Small Molecule Programs at the World Congress of Audiology in Paris (Businesswire)
18.09.24		Sensorion Reports 2024 First Half Results and Highlights Recent Updates (Businesswire)
12.09.24		Sensorion Announces Its Participation in the 59th Annual Inner Ear Biology Workshop (Businesswire)
02.09.24		Sensorion Announces its Participation in the World Congress of Audiology in September 2024 in Paris and will Lead a Symposium on Medical Advances in the Field of Hearing Loss (Businesswire)
05.08.24		Sensorion Announces its Participation in Stifel's Biotech Summer Summit (Businesswire)
15.07.24		Sensorion Announces New Positive Secondary Efficacy Endpoints Data From SENS-401 Phase 2a Clinical Trial For The Preservation Of Residual Hearing Loss (Businesswire)
27.06.24		Sensorion Announces the Appointment of Laurene Danon as Chief Financial Officer (Businesswire)
20.06.24		Sensorion Announces Upcoming Presentation of Promising SENS-401 Results at the Next International Conference on Cochlear Implants and Other Implantable Technologies (Businesswire)
30.05.24		Sensorion Publishes Results of Combined Shareholders’ General Meeting Resolutions (Businesswire)
28.05.24		Sensorion Announces its Participation in Upcoming Investor Conferences in June 2024 (Businesswire)
07.05.24		Sensorion Provides Preliminary Documents for the Combined Shareholders’ General Meeting of May 29, 2024 (Businesswire)
26.04.24		Sensorion Announces its Participation in the American Society of Cell and Gene Therapy (ASGCT) Annual Meeting (Businesswire)
10.04.24		Sensorion Announces its Participation in the Van Lanschot Kempen's Life Sciences Conference (Businesswire)
08.04.24		Sensorion Announces a €15 Million Financing, Extending Cash Runway Until the End of 2025 (Businesswire)
21.03.24		Sensorion Announces the Availability of Its Letter to Shareholders (Businesswire)
15.03.24		Sensorion Announces its Participation in the Annual Bioprocessing Summit Europe (Businesswire)
14.03.24		Sensorion Announces the Availability of its Financial Report for 2023 (Businesswire)
14.03.24		Sensorion Reports Full-Year 2023 Financial Results and Business Update (Businesswire)
11.03.24		Sensorion Announces it Has Met Primary Endpoint for SENS-401 Phase 2a Clinical Study for Residual Hearing Preservation (Businesswire)
06.03.24		Sensorion Will Host a Webcast on March 14, 2024, to Announce its 2023 Annual Financial Results (Businesswire)
29.02.24		Sensorion Announces its Participation in the Leerink Partners Global Biopharma Conference (Businesswire)
09.02.24		Sensorion Announces a €50.5 Million Financing With Participation From New and Existing US and European Healthcare Specialist Investors (Businesswire)
01.02.24		Sensorion Announces the Completion of Patient Inclusion in Phase 2a Clinical Trial of SENS-401 for Residual Hearing Preservation After Cochlear Implantation (Businesswire)
29.01.24		Sensorion Announces its Participation in the Association for Research in Otolaryngology ARO 47th Annual Midwinter Meeting (Businesswire)
25.01.24		Sensorion Appoints Dr. Federico Mingozzi as Non-Executive Director to the Board of Directors (Businesswire)
24.01.24		Sensorion Announces Amended Terms for the Warrants Issued in Connection With the Private Placement Completed in August 2023 (Businesswire)
19.01.24		Sensorion Announces Approval to Initiate Lead Gene Therapy Candidate SENS-501 (OTOF-GT) into a Phase 1/2 Clinical Trial in some European Countries (Businesswire)
05.01.24		Sensorion Announces Partnership With the Institut Pasteur to Accelerate Gene Therapy Programs Targeting Hearing Disorders Has Been Extended for Five Years (Businesswire)
21.12.23		Sensorion Publishes Results of Combined General Meeting Resolutions (Businesswire)
18.12.23		Sensorion Provides an Update on NOTOXIS, its Proof of Concept Phase 2a Clinical Trial of SENS-401 in Cisplatin-Induced Ototoxicity (CIO) (Businesswire)
12.12.23		Sensorion Appoints CMC Expert Bernd Schmidt as New Chief Technical Officer (Businesswire)
30.11.23		Sensorion Provides Preliminary Documents for the Combined Shareholders’ General Meeting of December 20, 2023 (Businesswire)
23.11.23		Sensorion Announces Its Attendance at the 42nd Annual J.P. Morgan Healthcare Meeting in San Francisco (Businesswire)
25.10.23		Sensorion to Participate in the Jefferies London Healthcare Conference and McDermott Will & Emery’s Life Sciences Symposium (Businesswire)
18.10.23		Sensorion Will Present At The European Society Of Gene & Cell Therapy (ESGCT) Conference (Businesswire)
26.09.23		Sensorion Announces the Availability of Its Financial Report for the 1st Half of 2023 (Businesswire)
21.09.23		Sensorion Announces Webconference on September 25, 2023, and its Participation in Upcoming Investor Conferences in October 2023 (Businesswire)
20.09.23		Sensorion Reports 2023 First Half Results (Businesswire)
19.07.23		Sensorion Submits Clinical Trial Application for OTOF-GT, its Lead Gene Therapy Candidate, in Europe (Businesswire)
10.07.23		Sensorion Submits Clinical Trial Application for Lead Gene Therapy Candidate OTOF-GT in the UK (Businesswire)
19.06.23		Sensorion Reports Promising Preliminary Data from SENS-401 Phase 2a Clinical Study (Businesswire)
07.06.23		Sensorion to Host Key Opinion Leader Webinar on July 5, 2023; Confirms Upcoming Key Milestones (Businesswire)
25.05.23		Sensorion Publishes Results of Combined Shareholders’ General Meeting Resolutions (Businesswire)
11.05.23		Sensorion Will Present Two Posters At The American Society Of Cell And Gene Therapy (ASGCT) 26th Annual Meeting (Businesswire)
03.05.23		Sensorion Provides Preliminary Documents for the Combined Shareholders’ General Meeting of May 24, 2023 (Businesswire)

1 | Weiter

Newssuche

Meistgelesene Nachrichten

Drohende Korrektur? Experte schlägt Alarm bei der NVIDIA-Aktie

Flugzeugabsturz nahe Vilnius: DHL-Auftragnehmer in schweren Unfall verwickelt - DHL-Aktie etwas schwächer

Italiens UniCredit will Banco BPM schlucken - Scheitert jetzt die Commerzbank-Übernahme? - Aktien unter Druck

Pierer Mobility-Aktie zieht zweistellig an: Pierer Industrie AG hat Restrukturierungsverfahren eingeleitet

Bitcoin im Fokus: MicroStrategy sorgt für Spannung mit potenziellen Käufen

Erstes Alarmsignal seit 2008: Droht dem Aktienmarkt eine Krise?

finanzen.net Apps

ETF-Sparplan

Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.

JETZT MEHR ERFAHREN

Aktien ATX DAX EuroStoxx 50 Dow Jones NASDAQ 100 Nikkei 225 S&P 500

Kontakt - Impressum - Werbung

Sitemap - Datenschutz - Disclaimer - AGB - Privatsphäre-Einstellungen

Für die aufgeführten Inhalte kann keine Gewährleistung für die Vollständigkeit, Richtigkeit und Genauigkeit übernommen werden.
Kursinformationen von SIX Financial Information Deutschland GmbH. Verzögerung 15 Min. (Nasdaq, NYSE: 20 Min.).
© 1999-2024 finanzen.net GmbH

*Werbehinweise: Die Billigung des Basisprospekts durch die Bundesanstalt für Finanzdienstleistungsaufsicht ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.

⁵Hinweis zu Plus500: 82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren. Plus500UK Ltd ist zugelassen und reguliert durch Financial Conduct Authority (FRN 509909). Plus500CY Ltd authorized & regulated by CySEC (#250/14).

Währungsrechner News Devisen Dollarkurs Aktienkurse Bitcoin Rohstoffe Fonds

Portfolioname: Watchlistname:
Portfolio:
Name:
Typ:
ISIN:
Börse:
Anzahl:
Aktueller Kurs:
Kurszeit:
Kaufpreis:
Kaufdatum:	27.11.2024 19:42
Kaufwert:	EUR
	Hinzufügen Speichern